

## **Supplementary material**

---

*Rekosz J, Karwowski J, Kowalik I, et al. Risk factors for thrombus and spontaneous echocardiographic contrast with sludge among atrial fibrillation patients treated with oral anticoagulants before electrical cardioversion. Pol Heart J. 2024.*

Please note that the journal is not responsible for the scientific accuracy or functionality of any supplementary material submitted by the authors. Any queries (except missing content) should be directed to the corresponding author of the article.

**Table S1.** Characteristics of the study group depending on the gender

	Female n = 172	Male n = 128	P-value
Age, years, mean (SD)	76.4 (8.0)	71.3 (9.9)	<b>&lt;0.001</b>
BMI ( $\text{kg}/\text{m}^2$ ), mean (SD)	30.1 (5.9)	28.9 (4.7)	0.08
<b>Comorbidities</b>			
CAD, n (%)	28 (16.3)	48 (37.5)	<b>&lt;0.001</b>
MI, n (%)	7 (4.1)	23 (18.0)	<b>&lt;0.001</b>
AH, n (%)	140 (81.4)	92 (71.9)	0.07
DM, n (%)	60 (35.1)	35 (27.3)	0.19
PE, n (%)	2 (1.2)	2 (1.6)	1.00
DVT, n (%)	3 (1.8)	3 (2.3)	1.00
History of stroke/TIA, n (%)	7 (4.1)	14 (10.9)	<b>0.04</b>
Thyroid disease, n (%)	48 (28.1)	11 (8.6)	<b>&lt;0.001</b>

CKD, n (%)	55 (32.3)	24 (18.7)	<b>0.01</b>
Laboratory tests			
Hgb (g/dL), mean (SD)	13.5 (1.6)	14.4 (1.7)	<b>&lt;0.001</b>
WBC (K/uL), median (IQR)	7.5 (6.4–9.0)	6.9 (5.9–8.2)	<b>0.03</b>
PLT (K/uL), median (IQR)	221 (186–269)	194 (151–234)	<b>&lt;0.001</b>
GFR (ml/min/1.73 m <sup>2</sup> ), median (IQR)	60 (48–60)	60 (60–60)	<b>&lt;0.001</b>
LDL cholesterol, mg/dL, median (IQR)	75 (57–105)	78 (57–98)	0.93
AspAT, U/L, median (IQR)	23 (18–33)	23 (18.5–32)	0.80
AlAT, U/L, median (IQR)	23 (15–32)	24 (18–32)	0.20
TSH, uIU/mL, median (IQR)	1.64 (0.97–2.66)	1.43 (0.76–2.16)	0.18
<b>Pharmacotherapy</b>			
ASA, n (%)	18 (10.5%)	23 (28.0%)	0.09
Clopidogrel, n (%)	2 (1.2%)	7 (5.5%)	0.07
Ticagrelor, n (%)	1 (0.6%)	0 (0)	1.0
BB, n (%)	140 (81.4)	91 (71.1)	<b>0.05</b>
ACE-I, n (%)	67 (38.9)	43 (33.6)	0.41
ARB-AT1, n (%)	49 (28.6)	37 (28.9)	1.00

Ca-bloker, n (%)	57 (33.1)	33 (25.8)	0.21
Thyroid hormone, n (%)	43 (25.0)	7 (5.5)	<b>&lt;0.001</b>
Anti-thyroid drugs n (%)	3 (1.7)	4 (3.1)	0.46
PPI, n (%)	47 (27.5)	28 (21.9)	0.33
<b>CHA<sub>2</sub>DS<sub>2</sub>-VASc score</b> , median (IQR)	4 (3–5)	3 (2–5)	<b>&lt;0.001</b>
<b>Type of AF</b>			
Paroxysmal AF, n (%)	118 (68.6)	66 (51.6)	<b>0.004</b>
Persistent AF, n (%)	110 (63.9)	83 (64.8)	0.97
<b>SEC / Thrombus</b>			
Thrombus, n (%)	7 (4.1)	7 (5.5)	0.77
SEC 4+, n (%)	30 (17.4)	19 (14.8)	0.66
SEC 4+/T, n (%)	35 (20.3)	21 (16.4)	0.47

Abbreviations: ACE-I, angiotensin converting enzyme inhibitor; AH, arterial hypertension; ALT, alanine aminotransferase; ARB, angiotensin receptor blocker – AT1; ASA, acetylsalicylic acid; AST, aspartate aminotransferase; BB, beta blocker; CAD, coronary artery disease; CKD, chronic kidney disease; DM, diabetes mellitus; DVT, deep venous thrombosis; GFR, glomerular filtration rate; Hgb, hemoglobin; PPI, proton-pump inhibitor; IQR, interquartile range; LDL, low density lipoprotein; PE, pulmonary embolism; PLT, platelets; SEC, spontaneous echocardiographic contrast; T, thrombus; TIA, transient ischemic attack; TSH, thyroid-stimulating hormone; WBC, white blood cells

**Table S2.** Results of TTE and TEE parameters in a group of men and women

	Female n = 172	Male n = 128	P-value
--	-------------------	-----------------	---------

<b>TTE</b>			
LVEF, %, mean (95% CI)	58.3 (57.1–59.5)	51.7 (49.7–53.8)	<0.001
LA <sub>l</sub> , cm, mean (95% CI)	5.3 (5.2–5.4)	5.5 (5.4–5.6)	<0.001
LAa 4CH, cm <sup>2</sup> , mean (95% CI)	24.1 (23.5–24.7)	26.9 (26.0–27.7)	<0.001
LAV, mL, mean (95%CI)	76.9 (73.8–80.0)	90.7 (86.1–95.3)	<0.001
LAVI, mL/m <sup>2</sup> , mean (95% CI)	42.3 (40.6–44.0)	44.0 (41.9–46.1)	0.24
<b>TEE</b>			
LA <sub>Al</sub> , cm, mean (95% CI)	2.9 (2.8–3.0)	3.0 (2.9–3.1)	0.48
LA <sub>Ao</sub> , cm, mean (95 % CI)	1.49 (1.44–1.54)	1.46 (1.41–1.52)	0.54
LA <sub>Aflv</sub> min, cm/s, mean (95% CI)	25.5 (24.2–26.8)	27.2 (25.3–29.2)	0.50
LA <sub>Aflv</sub> max, cm/s, mean (95% CI)	39.9 (37.8–41.9)	44.5 (40.7–48.4)	0.036

Abbreviations: : LA<sub>Aflv</sub> max., left atrium appendage flow velocity max. ; LA<sub>Aflv</sub> min., left atrium appendage flow velocity min.; LA<sub>Al</sub>, left atrium appendage length; LA<sub>Ao</sub>, left atrium appendage ostium; LAa 4CH, left atrium area from 4 chamber views; LA<sub>l</sub> 4CH, left atrium length from 4 chamber views; LAw 4CH, left atrium width from 4 chamber views; LAV, left atrium volume; LAVI, left atrium volume index; LVEF, left ventricular ejection fraction; TEE, transesophageal echocardiography; TTE, transthoracic echocardiography